Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-06-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-0635PMID 24907113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

  2013cited by this paper
• Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation

  2013cited by this paper
• HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function

  2013cited by this paper
• Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production

  2013cited by this paper
• Activated monocytes augment TRAIL‐mediated cytotoxicity by human NK cells through release of IFN‐γ

  2013cited by this paper
• Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.

  2013cited by this paper
• Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

  2013cited by this paper
• Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

  2013cited by this paper
• Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

  2013cited by this paper
• Miniatures Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase 1 Production

  2013cited by this paper
• Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

  2013cited by this paper
• Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity.

  2012cited by this paper
• On the armament and appearances of human myeloid-derived suppressor cells.

  2012cited by this paper
• Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC)

  2012cited by this paper
• Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

  2012cited by this paper
• Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.

  2012influential reference
• Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

  2011cited by this paper
• Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function.

  2011cited by this paper
• A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

  2011cited by this paper
• Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

  2011cited by this paper
• Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

  2010cited by this paper
• COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

  2010cited by this paper
• Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.

  2010cited by this paper
• Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

  2010cited by this paper
• PGE2 receptor EP2 mediates the antagonistic effect of COX‐2 on TGF‐β signaling during mammary tumorigenesis

  2010cited by this paper
• Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1

  2009cited by this paper
• Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11

  2009cited by this paper
• Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

  2008cited by this paper
• Expression Analysis of the Prostaglandin E2 Production Pathway in Human Pancreatic Cancers

  2008cited by this paper
• Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1

  2008cited by this paper
• Cancer-related inflammation

  2008cited by this paper
• Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.

  2008cited by this paper
• Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host.

  2007cited by this paper
• Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor.

  2007cited by this paper
• The CD16−CD56bright NK Cell Subset Is Resistant to Reactive Oxygen Species Produced by Activated Granulocytes and Has Higher Antioxidative Capacity Than the CD16+CD56dim Subset1

  2007cited by this paper
• The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

  2007cited by this paper
• Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma

  2007cited by this paper
• Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.

  2007cited by this paper
• Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

  2007cited by this paper
• Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.

  2006cited by this paper
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  2005cited by this paper
• Increased Susceptibility to Apoptosis of CD56dimCD16+ NK Cells Induces the Enrichment of IFN-γ-Producing CD56bright Cells in Tuberculous Pleurisy1

  2005cited by this paper
• Determination of subcutaneous tumor size in athymic (nude) mice

  2004cited by this paper
• PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP.

  2004cited by this paper
• EP2 and EP4 prostanoid receptor signaling.

  2003cited by this paper
• Cyclooxygenase-2 in human pathological disease.

  2002cited by this paper
• American Association for Cancer Research

  2000cited by this paper

• The transcriptional repressor Fli1 inhibits proteostasis during nutrient stress to limit NK cell persistence in solid tumors.

  2026cites this paper
• Molecular Targets for Cancer Immunotherapy: Focusing on (Immune and Tumor) Cell-Derived Metabolites

  2026cites this paper
• Indomethacin exerts both cyclooxygenase inhibition-dependent and independent mechanisms to enhance chemo-immunotherapy in mice

  2026cites this paper
• The cell’s autonomous response window for advanced healing

  2025cites this paper
• Identification of Natural Killer Cell Enhancers Through Mimicking of the Tumor Microenvironment.

  2025cites this paper
• Breaking Immune Evasion in Breast Cancer by Targeting COX-2/PGE2 Pathway.

  2025cites this paper
• Peripheral nerves-cancer cross-talk: the next frontier in cancer treatment

  2025cites this paper
• Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy

  2025cites this paper
• Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment

  2025cites this paper
• Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations

  2025cites this paper
• Microbial-induced trained immunity for cancer immunotherapy.

  2025cites this paper
• Extracellular Vesicle-Based Strategies for Tumor Immunotherapy

  2025cites this paper
• Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy

  2025cites this paper
• CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization

  2025cites this paper
• Multifaceted role of myeloid-derived suppressor cells in colorectal cancer.

  2025cites this paper
• Celecoxib in oncology: targeting the COX-2/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy

  2025cites this paper
• Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells

  2025cites this paper
• EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells

  2024influential citation
• Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

  2024cites this paper
• Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4

  2024cites this paper
• Myeloid-derived suppressor cells in cancer and cancer therapy

  2024cites this paper
• EP2/EP4 targeting prevents tumor-derived PGE2-mediated immunosuppression in cDC2s.

  2024cites this paper
• MSC microvesicles loaded G-quadruplex-enhanced circular single-stranded DNA-9 inhibits tumor growth by targeting MDSCs

  2024cites this paper
• Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis

  2024cites this paper
• Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization

  2024cites this paper
• The impact of trauma relevant concentrations of prostaglandin E2 on the anti-microbial activity of the innate immune system

  2024cites this paper
• Immunity against Non-Melanoma Skin Cancer and the Effect of Immunosuppressive Medication on Non-Melanoma Skin Cancer Risk in Solid Organ Transplant Recipients

  2023cites this paper
• Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+ myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model.

  2023cites this paper
• The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer

  2023cites this paper
• The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis

  2023cites this paper
• IL-1 receptor–associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy

  2023cites this paper
• KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity

  2023cites this paper
• The unfolding story of dying tumor cells during cancer treatment

  2023cites this paper
• Tumor Microenvironment Sequential Drug/Gene Delivery Nanosystem for Realizing Multistage Boosting of Cancer-Immunity Cycle on Cancer Immunotherapy.

  2023cites this paper
• Exploiting innate immunity for cancer immunotherapy

  2023cites this paper
• Immunomodulatory actions of myeloid-derived suppressor cells in the context of innate immunity

  2023cites this paper
• Netrin-1 promotes the immunosuppressive activity of MDSCs in colorectal cancer.

  2023cites this paper
• Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress

  2023cites this paper
• Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis

  2023cites this paper
• Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions

  2023cites this paper
• MDSCs: The Key Players in the Formation of Pre-Metastatic Niche.

  2023cites this paper
• Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells

  2023cites this paper
• Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

  2023cites this paper
• Chimeric antigen receptor engineered natural killer cells for cancer therapy

  2023cites this paper
• Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics

  2023cites this paper
• Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells

  2023cites this paper
• NK cells direct the perspective approaches to cancer immunotherapy

  2023influential citation
• Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review

  2022cites this paper
• PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review

  2022cites this paper
• The role of PGE2 and EP receptors on lung's immune and structural cells; possibilities for future asthma therapy.

  2022cites this paper
• Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E2 and suppress tumor growth in medulloblastoma.

  2022cites this paper
• Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox

  2022cites this paper
• Coordinated Regulation of Myeloid-Derived Suppressor Cells by Cytokines and Chemokines

  2022cites this paper
• Fetus, as an allograft, evades the maternal immunity.

  2022cites this paper
• Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments

  2022cites this paper
• The Interaction of Human Papillomavirus Infection and Prostaglandin E2 Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics

  2022cites this paper
• Overcoming tumor resistance mechanisms in CAR-NK cell therapy

  2022cites this paper
• Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

  2022cites this paper
• Macrophages Use Apoptotic Cell-Derived Methionine and DNMT3A During Efferocytosis to Promote Tissue Resolution

  2022cites this paper
• Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review)

  2022cites this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

  2022cites this paper
• NK cells and solid tumors: therapeutic potential and persisting obstacles

  2022influential citation
• Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

  2022cites this paper
• TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition

  2022cites this paper
• Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer

  2022cites this paper
• Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy

  2022cites this paper
• Surgery-Mediated Tumor-Promoting Effects on the Immune Microenvironment.

  2022cites this paper
• Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies

  2021cites this paper
• Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy

  2021cites this paper
• New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs

  2021cites this paper
• Complete rejection of large established breast cancer by local immunochemotherapy with T cell activation against neoantigens

  2021cites this paper
• Targeting HDL in tumor microenvironment: New hope for cancer therapy

  2021influential citation
• High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-β1

  2021influential citation
• Transforming growth factor‐beta1 and myeloid‐derived suppressor cells: A cancerous partnership

  2021cites this paper
• Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment

  2021cites this paper
• Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment

  2021cites this paper
• Immunosuppressive Myeloid Cells Induce Nitric Oxide–Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells

  2021cites this paper
• Characterization of the Signaling Modalities of Prostaglandin E2 Receptors EP2 and EP4 Reveals Crosstalk and a Role for Microtubules

  2021cites this paper
• A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death.

  2021cites this paper
• Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy

  2021influential citation
• Metabolic Rewiring in the Tumor Microenvironment to Support Immunotherapy: A Focus on Neutrophils, Polymorphonuclear Myeloid-Derived Suppressor Cells and Natural Killer Cells

  2021cites this paper
• The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors

  2021cites this paper
• Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

  2021cites this paper
• Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy

  2021cites this paper
• Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

  2021cites this paper
• CCID_A_285564 209..216

  2021influential citation
• Proteomic signatures of myeloid derived suppressor cells from liver and lung metastases reveal functional divergence and potential therapeutic targets

  2021cites this paper
• Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics

  2021cites this paper
• Leveraging NKG2D Ligands in Immuno-Oncology

  2021cites this paper
• Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy

  2021influential citation
• ERO1L Is a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment

  2021cites this paper
• Regulatory role of methionine enkephalin in myeloid-derived suppressor cells and macrophages in human cutaneous squamous cell carcinoma.

  2021cites this paper
• Immunometabolic targeting of NK cells to solid tumors

  2021cites this paper
• Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells

  2021cites this paper
• Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy

  2021cites this paper
• Electroacupuncture regulates inflammatory cytokines by activating the vagus nerve to enhance antitumor immunity in mice with breast tumors.

  2021cites this paper
• MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer

  2021cites this paper
• Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients

  2021cites this paper
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

  2021cites this paper